The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BIIB | -17.42% | -40.65% | -9.9% | +5,168% |
| S&P | +17.35% | +108.64% | +15.84% | +1,670% |
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.56B | 8.9% |
| Gross Profit | $1.76B | 6.9% |
| Gross Margin | 68.80% | -1.3% |
| Market Cap | $18.40B | -45.5% |
| Market Cap / Employee | $2.42M | 0.0% |
| Employees | 7.6K | 0.5% |
| Net Income | $634.80M | 8.8% |
| EBITDA | $1.04B | 28.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.76B | 44.5% |
| Accounts Receivable | $2.08B | 0.3% |
| Inventory | 2.3K | -9.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.59B | -1.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 5.55% | 1.1% |
| Return On Invested Capital | 11.71% | -5.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $134.30M | -77.3% |
| Operating Free Cash Flow | $160.90M | -74.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 17.51 | 13.68 | 13.51 | 12.01 | -58.85% |
| Price to Book | 1.73 | 1.36 | 1.19 | 1.08 | -51.16% |
| Price to Sales | 3.07 | 2.41 | 2.13 | 1.92 | -47.36% |
| Price to Tangible Book Value | 417.79 | 329.59 | 36.55 | 20.06 | -58.34% |
| Price to Free Cash Flow TTM | 14.54 | 8.21 | 8.23 | 9.31 | -56.91% |
| Enterprise Value to EBITDA | 49.03 | 43.42 | 31.22 | 21.39 | -55.01% |
| Free Cash Flow Yield | 6.9% | 12.2% | 12.1% | 10.7% | 132.09% |
| Return on Equity | 10.5% | 10.4% | 9.2% | 9.1% | 19.63% |
| Total Debt | $6.65B | $6.72B | $6.62B | $6.59B | -0.97% |
We examine three biotech companies' past performances and future outlooks.
The biotech popped 30% after the extremely unusual revival of an Alzheimer's treatment that had looked like a failure at first.
Competitors make headway against Teva Pharmaceutical's top seller, and Biogen's hemophilia drugs become Bioverativ. Here's what you should know.
The Industry Focus team compares Biogen's and Celgene's current valuations and considers what might be in store for Gilead Sciences now that its new hepatitis C drug is approved.
BIIB earnings call for the period ending December 31, 2024.
BIIB earnings call for the period ending September 30, 2024.
BIIB earnings call for the period ending June 30, 2024.
BIIB earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
